Country for PR: United States
Contributor: PR Newswire New York
Tuesday, June 19 2012 - 20:01
AsiaNet
TriReme Medical Receives FDA Clearance for Expanded Matrix of Sizes of Chocolate PTA Balloon Catheter
PLEASANTON, Calif., June 19, 2012 /PRNewswire-AsiaNet/ --

TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance 
for an expanded matrix of sizes for its Chocolate(TM) PTA balloon catheter. 
Chocolate(TM) is now approved for the percutaneous transluminal treatment of 
lesions in the peripheral vasculature in balloon diameters from 2.0 - 4.0mm and 
in balloon lengths up to 120mm.

"This latest regulatory approval broadening the available size matrix of the 
Chocolate(TM) PTA Balloon marks yet another important milestone for TriReme 
Medical," said Eitan Konstantino, President and CEO of TriReme Medical Inc. 
"There is more to come; our goal is to provide a broad range of innovative 
tools to improve outcomes in patients suffering from complex vascular disease."

"Chocolate(TM) has become an essential part of my routine practice for treating 
below the knee lesions," said Dr. Rajesh Dave, Chief Medical Executive and 
Director at Cardiac Catheterization Laboratories, Holy Spirit Cardiovascular 
Institute, Camp Hill, PA. "With the approval of these new sizes, I will be able 
to expand my use of Chocolate(TM) and begin to treat patients with disease in 
the popliteal artery where we usually prefer not to stent."

About Chocolate(TM): Chocolate's novel design incorporates a constraining 
structure over a semi-compliant balloon to facilitate the formation of small 
modules ("pillows"). Through this advanced mechanism of action, Chocolate 
minimizes shear stress and allows for uniform inflation and rapid deflation. 
The Chocolate "pillows" can expand locally to facilitate plaque modification 
and are designed to lower the strain and trauma induced on the vessel wall.

About TriReme Medical, Inc. 
Based in Pleasanton, California and Singapore, TriReme Medical, Inc. is a 
privately held medical device company dedicated to the development, 
manufacturing, and commercialization of next generation percutaneous devices 
for the treatment of complex coronary and peripheral arterial disease. The 
company is focused on the US and the emerging Asian markets.

SOURCE  TriReme Medical, Inc.

CONTACT: Gail Prince, +1-925-931-1300 ext 208, gprince@trirememedical.com
Translations

Japanese